Trial · NCT01021813
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase | Suvorexant | 0.0 | percentage of participants | ||
| Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase | Placebo | 0.0 | percentage of participants | ||
| Percentage of Participants Who Experienced Sleep Paralysis AEs During the DB Treatment Phase | Suvorexant | 0.4 | percentage of participants | ||
| Percentage of Participants Who Experienced Sleep Paralysis AEs During the DB Treatment Phase | Placebo | 0.0 | percentage of participants | ||
| Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs During the DB Treatment Phase | Suvorexant | any complex sleep-related behaviors | 0.2 | percentage of participants | |
| Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs During the DB Treatment Phase | Placebo | any complex sleep-related behaviors | 0.0 | percentage of participants | |
| Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs During the DB Treatment Phase | Suvorexant | somnambulism | 0.2 | percentage of participants | |
| Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs During the DB Treatment Phase | Placebo | somnambulism | 0.0 | percentage of participants | |
| Percentage of Participants Who Experienced Falls AEs During the DB Treatment Phase | Suvorexant | 2.3 | percentage of participants | ||
| Percentage of Participants Who Experienced Falls AEs During the DB Treatment Phase | Placebo | 3.1 | percentage of participants | ||
| Percentage of Participants Who Experienced Suicidal Ideation and/or Behavior AEs During the DB Treatment Phase | Suvorexant | 0.8 | percentage of participants | ||
| Percentage of Participants Who Experienced Suicidal Ideation and/or Behavior AEs During the DB Treatment Phase | Placebo | 0.0 | percentage of participants | ||
| Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase | Suvorexant | Any hypnagogic/hypnopompic hallucinations AEs | 0.8 | percentage of participants | |
| Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase | Placebo | Any hypnagogic/hypnopompic hallucinations AEs | 0.0 | percentage of participants | |
| Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase | Suvorexant | Hypnagogic hallucination | 0.6 | percentage of participants | |
| Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase | Placebo | Hypnagogic hallucination | 0.0 | percentage of participants | |
| Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase | Suvorexant | Hypnopompic hallucination | 0.2 | percentage of participants | |
| Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs During the DB Treatment Phase | Placebo | Hypnopompic hallucination | 0.0 | percentage of participants | |
| Percentage of Participants Who Experienced Selected AEs Associated With Potential for Abuse During the DB Treatment Phase | Suvorexant | any selected AE of potential abuse | 3.5 | percentage of participants | |
| Percentage of Participants Who Experienced Selected AEs Associated With Potential for Abuse During the DB Treatment Phase | Placebo | any selected AE of potential abuse | 3.9 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01021813/results